Victoria Socha

DocwireNews

Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anemia in chronic kidney disease (CKD). Tadao Akizawa, MD, PhD, and colleagues reported results of a post hoc analysis of a Japanese, open-label, partially randomized, phase 3 study in nondialysis dependent (NDD) CKD patients treated with traditional erythropoiesis-stimulating agents (ESAs). Results were reported online in the American Journal of Nephrology [doi.org/10.1159/000519043].The analysis assessed dosing trends of roxadustat and darbepoetin alfa (DA) required to maintain target hemoglobin (Hb) concentrations in patients with risk factors associated with ESA hyporesponsiveness. The 1517-CL-0310 study (NCT02988973) demonstrated the noninferiority of roxadustat to DAS for change from baseline in average Hb levels week 18 to 24. Patients in the study had used human recombinant erythropoietin or darbepoetin alfa before conversion were randomized to receive either roxadustat or DA.Study end points were the average allocated dose of roxadustat and DA per administration in the last 6 weeks (AAD/6W), assessed by subgroups known to be associated with ESA hyporesponsiveness. The analysis of variance was performed by the treatment group to test the influence of subgroup factors on the AAD/6W of study drug. The researchers calculated the ratios between the mean AAD/6W in each subgroup category and the within-arm mean AAD/6W.A total of 262 patients were randomized to either the roxadustat or DA comparative group and received treatment with roxadustat (n=131) or DA, (n=131). Higher mean doses of both roxadustat and DA were required in the highest quartile of ESA resistance (63.15 mg [P=.003] and 47.33 [P&lt;.001], respectively). The lowest doses for both roxadustat and DA were administered to patients with adequate iron repletion (45.54 mg and 28.13 mg, respectively).There were associations between high-sensitivity C-reactive protein &ge;28.57 nmol/L and estimated glomerular filtration rate &lt;15 mL/min/1.73 m2 and requiring&nbsp; higher dose of DA but not of roxadustat.In conclusion, the researchers said, &ldquo;The roxadustat dose required to maintain target hemoglobin in NDD patients in Japan with anemia of CKD relative to DA dose may not be impacted by low-grade inflammation. Roxadustat may be beneficial for ESA-hyporesponsive NDD CKD patients.&rdquo;

Jordana Jampel

Successful HIV Viral Suppression With At-Home Administration

Modernization and the Rising Burden of IBD: New Insights From a Global Study

Gastroenterology

FDA Approves Novel Blood Test for Alzheimer’s Detection

Dementia

Latest News

Post Hoc Analysis: Factors Affecting Doses of Roxadustat versus Darbepoetin Alfa

Anemia and Kidney Disease

Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anemia in chronic kidney disease (CKD). Tadao Akizawa, MD, PhD, and colleagues ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe